Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia

Bibliography

• Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Apr2.pdf [Last accessed 2015]
   Google Scholar
• Mapel DW, Hurley JS, Roblin D, et al. Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists. Respir Med 2006;100:595–609
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177(1):19–26
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184(6):662–71
   PubMed Web of Science ®Google Scholar
• Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2000;356:1480–5
   PubMed Web of Science ®Google Scholar
• Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007;29(5):906–13
   PubMed Web of Science ®Google Scholar
• Hospers JJ, Schouten JP, Weiss ST, et al. Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample. Am J Respir Crit Care Med 1999;160:1869–74
   PubMed Web of Science ®Google Scholar
• Chung KF. Salmeterol/fluticasone combination in the treatment of COPD. Int J Chron Obstruct Pulmon Dis 2006;1(3):235–42
   PubMedGoogle Scholar
• Burgel PR, Deslee G, Jebrak G, et al. Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011? Eur Respir J 2014;43:1201–3
   PubMed Web of Science ®Google Scholar
• Farr BM, Bartlett CL, Wadsworth J, et al. Risk factors for community-acquired pneumonia diagnosed upon hospital admission. Respir Med 2000;94(10):954–63
   PubMed Web of Science ®Google Scholar
• Gau JT, Acharya U, Khan S, et al. Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr 2010;10:45
   PubMed Web of Science ®Google Scholar
• Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006;28:346–51
   PubMed Web of Science ®Google Scholar
• Molinos L, Clemente MG, Miranda B, et al. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect 2009;58:417–24
   PubMed Web of Science ®Google Scholar
• Ernst P, González AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176(2):162–6
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008;102:1099–108
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr Opin Pulm Med 2010;16(2):118–22
   PubMed Web of Science ®Google Scholar
• Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009;374(9691):712–19
   PubMed Web of Science ®Google Scholar
• Halpin DM, Gray J, Edwards SJ, et al. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomized controlled trials. Int J Clin Pract 2011;65:764–74
   PubMed Web of Science ®Google Scholar
• Müllerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012;106(8):1124–33
   PubMed Web of Science ®Google Scholar
• Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009;169(3):219–29
   PubMed Web of Science ®Google Scholar
• Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300(20):2407–16
   PubMed Web of Science ®Google Scholar
• Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomized placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD study group. Lancet 1998;351:773–80
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl CG, Laitinen LA, et al. European respiratory society study on chronic obstructive pulmonary disease. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999;340:1948–53
   PubMed Web of Science ®Google Scholar
• Vestbo J, Sørensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 1999;353:1819–23
   PubMed Web of Science ®Google Scholar
• DiSantostefano RL, Sampson T, Le HV, et al. Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study. PLoS One 2014;9(5):e97149
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775–89
   PubMed Web of Science ®Google Scholar
• Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641–7
   PubMed Web of Science ®Google Scholar
• Calverley PM, Stockley RA, Seemungal TA, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011;139(3):505–12
   PubMed Web of Science ®Google Scholar
• Almirall J, Bolíbar I, Serra-Prat M, et al. Inhaled drugs as risk factors for community-acquired pneumonia. Eur Respir J 2010;36(5):1080–7
   PubMed Web of Science ®Google Scholar
• Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids and the risk of serious pneumonia. Thorax 2013;68:10129–36
   Google Scholar
• Festic E, Bansal V, Gajic O, et al. Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study. Mayo Clin Proc 2014;89:154–62
   PubMed Web of Science ®Google Scholar
• Mapel D, Schum M, Yood M, et al. Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators. Prim Care Respir J 2010;19(2):109–17
   PubMedGoogle Scholar
• Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;3:CD010115
   PubMed Web of Science ®Google Scholar
• Woodhead M. Inhaled corticosteroids cause pneumonia or do they? Am J Respir Crit Care Med 2007;176(2):111–12
   PubMed Web of Science ®Google Scholar
• Singanayagam A, Chalmers JD, Akram AR, Hill AT. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J 2011;38:36–41
   PubMed Web of Science ®Google Scholar
• Chen D, Restrepo MI, Fine MJ, et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med 2011;184:312–16
   PubMed Web of Science ®Google Scholar
• Liapikou A, Polverino E, Ewig S, et al. Severity and outcomes of hospitalized community-acquired pneumonia in COPD patients. Eur Respir J 2012;39:855–61
   PubMed Web of Science ®Google Scholar
• Sellares J, López-Giraldo A, Lucena C, et al. Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. Am J Respir Crit Care Med 2013;187(11):1241–8
   PubMed Web of Science ®Google Scholar
• Menéndez R, Torres A, Zalacaín R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004;59(11):960–5
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomized controlled trials. Lancet Respir Med 2013;1(3):210–23
   PubMed Web of Science ®Google Scholar
• Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175(2):144–9
   PubMed Web of Science ®Google Scholar
• Loke YK, Kwok CS, Wong JM, et al. Chronic obstructive pulmonary disease and mortality from pneumonia: meta-analysis. Int J Clin Pract 2013;67(5):477–87
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177(1):19–26
   PubMed Web of Science ®Google Scholar
• Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ 2013;346:f3306
   PubMed Web of Science ®Google Scholar
• Malo de Molina R, Mortensen EM, Restrepo MI, et al. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalized with pneumonia. Eur Respir J 2010;36:751–7
   PubMed Web of Science ®Google Scholar
• Joo MJ, Au DH, Fitzgibbon ML, Lee TA. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med 2010;104(2):246–52
   PubMed Web of Science ®Google Scholar
• Gutiérrez P, Closa D, Piner R, et al. Macrophage activation in exacerbated COPD with and without community-acquired pneumonia. Eur Respir J 2010;36(2):285–91
   PubMed Web of Science ®Google Scholar
• Barbier M, Agustí A, Alberti S. Fluticasone propionate reduces bacterial airway epithelial invasion. Eur Respir J 2008;32(5):1283–8
   PubMed Web of Science ®Google Scholar
• Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009;6:320–9
   PubMedGoogle Scholar
• Hubner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am 2005;25:469–88
   PubMed Web of Science ®Google Scholar
• Hogg JC, Chu FS, Tan WC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 2007;176(5):454–9
   PubMed Web of Science ®Google Scholar
• Finney L, Berry M, Singanayagam A, et al. Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. Lancet Respir Med 2014;2:919–32
   PubMed Web of Science ®Google Scholar
• Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J 2015;45(2):525–37
   PubMed Web of Science ®Google Scholar
• Keene ON, Vestbo J, Anderson JA, et al. Methods for therapeutic trials in COPD: lessons from the TORCH trial. Eur Respir J 2009;34:1018–23
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999;159:941–55
   PubMed Web of Science ®Google Scholar
• Sibila O, Laserna E, Mortensen EM, et al. Effects of inhaled corticosteroids on pneumonia severity and antimicrobial resistance. Respir Care 2013;58(9):1489–94
   PubMed Web of Science ®Google Scholar
• Patterson CM, Morrison RL, D’Souza A, et al. Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella pneumoniae in mice. Respir Res 2012;13:40
   PubMed Web of Science ®Google Scholar
• Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465–71
   PubMed Web of Science ®Google Scholar
• Marin A, Garcia-Aymerich J, Sauleda J, et al. Effect of bronchial colonisation on airway and systemic inflammation in stable COPD. COPD 2012;9:121–30
   PubMedGoogle Scholar
• Miravitlles M, Marin A, Monso E, et al. Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease. Respir Res 2010;11:58
   PubMedGoogle Scholar
• Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012;67:1075–80
   PubMed Web of Science ®Google Scholar
• Marin A, Monso E, Garcia-Nunez M, et al. Variability and effects of bronchial colonization in patients with moderate COPD. Eur Respir J 2010;35(2):295–302
   PubMed Web of Science ®Google Scholar
• Costelloe C, Metcalfe C, Lovering A, et al. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 2010;340:c2096
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. Available from: www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf [Last accessed 12 August 2014]
   Google Scholar
• Burgel PR, Paillasseur JL, Caillaud D, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010;36:531–9
   PubMed Web of Science ®Google Scholar
• Weiner P, Weiner M, Azgad Y, Zamir D. Inhaled budesonide therapy for patients with stable COPD. Chest 1995;108:1568–71
   PubMed Web of Science ®Google Scholar
• Leigh R, Pizzichini MM, Morris MM, et al. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006;27:964–71
   PubMed Web of Science ®Google Scholar
• Brightling CE, McKenna S, Hardagon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pumonary disease. Thorax 2005;60:193–8
   PubMed Web of Science ®Google Scholar
• Marc M. Arguments in favor of inhaled corticosteroids in COPD by phenotype instead of by severity. Arch Bronconeumol 2011;47(6):271–3
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee YK, Kim EK, et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med 2010;104:542–9
   PubMed Web of Science ®Google Scholar
• Nair P. Update on clinical inflammometry for the management of airway diseases. Can Respir J 2013;20:117–20
   PubMed Web of Science ®Google Scholar
• Weatherall M, Travers J, Shirtcliffe PM, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 2009;34:812–18
   PubMed Web of Science ®Google Scholar
• Crim C, Dransfield MT, Bourbeau J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc 2015;12(1):27–34
   PubMed Web of Science ®Google Scholar
• Jarad NA, Wedzicha JA, Burge PS, et al. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir Med 1999;93:161–6
   PubMed Web of Science ®Google Scholar
• Magnussen H, Watz H, Kirsten A, et al. Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale. Respir Med 2014;108(4):593–9
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014;371(14):1285–94
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish COPD guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish society of pulmonology and thoracic surgery. Arch Bronconeumol 2012;48(7):247–57
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Pedersen S, Carlsson LG, et al. Risks of pneumonia in patients with asthma taking inhaled corticosteroids. Am J Respir Crit Care Med 2011;183(5):589–95
   PubMed Web of Science ®Google Scholar